NCT00131014

Brief Summary

The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,500

participants targeted

Target at P75+ for all trials

Timeline
81mo left

Started Aug 2004

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress77%
Aug 2004Jan 2033

Study Start

First participant enrolled

August 9, 2004

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

August 15, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 17, 2005

Completed
27.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2033

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2033

Last Updated

April 24, 2026

Status Verified

April 1, 2026

Enrollment Period

28.4 years

First QC Date

August 15, 2005

Last Update Submit

April 21, 2026

Conditions

Non-Hodgkin's LymphomaHodgkin's DiseaseLeukemia, Lymphocytic, ChronicLymphoproliferative Disorders

Keywords

Non-Hodgkin's LymphomaHodgkin's diseaseChronic Lymphocytic LeukemiaLymphoproliferative disorderGenetics

Outcome Measures

Primary Outcomes (1)

  • Genetic factors that contribute to the development of lymphomas and CLL

    Genetic factors that contribute to the development of lymphomas and CLL

    Indefinite

Study Arms (3)

Next of Kin of deceased subj by lymphoma

Next of Kin of deceased subject by lymphoma

Subject unaffected by lymphoma

Subject unaffected by lymphoma

Subject affected by lymphoma

Subject affected by lymphoma

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Group 1: Next of kin of a relative who has died from lymphoma Group 2: Subjects who have a next of kin diagnosed with lymphoma and/or CLL Group 3: Subjects who have had or have non-Hodgkin's lymphoma, CLL or Hodgkin's disease and had a relative who also had lymphoma or CLL

You may qualify if:

  • Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed.
  • Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study.
  • Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research.
  • Age \> 18 years

You may not qualify if:

  • Subjects without a family history of lymphoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood Cheek cells Paraffin blocks of tumor tissue

MeSH Terms

Conditions

Lymphoma, Non-HodgkinHodgkin DiseaseLeukemia, Lymphocytic, Chronic, B-CellLymphoproliferative Disorders

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesLeukemia, B-CellLeukemia, LymphoidLeukemiaHematologic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jennifer R. Brown, MD, PhD

    Dana-Farber Cancer Institute

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Celeste Carey, MS

CONTACT

857-215-1646celeste_carey@dfci.harvard.edu

Jennifer Brown, MD PhD

CONTACT

617-632-4564Jennifer_Brown@dfci.harvard.edu

Study Design

Study Type
observational
Observational Model
FAMILY BASED
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Medicine

Study Record Dates

First Submitted

August 15, 2005

First Posted

August 17, 2005

Study Start

August 9, 2004

Primary Completion (Estimated)

January 1, 2033

Study Completion (Estimated)

January 1, 2033

Last Updated

April 24, 2026

Record last verified: 2026-04

Locations

US(1)